Eli Lilly and Pfizer Enter China's First Commercial Insurance Innovative Drug List, Unlocking New Market Opportunities

Eli Lilly, Pfizer, and Johnson & Johnson Selected for China's First Commercial Insurance Innovative Drug List, Opening New Market Channels and Boosting Sales Prospects for Expensive Cutting-Edge Therapies.

A total of 19 drugs made it onto this list, including some that are too expensive for national medical insurance to cover but are recommended to be included in commercial medical insurance. These drugs are used to treat a range of diseases, including cancer and Alzheimer's, as well as rare genetic disorders.

As China's population ages, the growing demand for treatments for diseases such as cancer, diabetes, and dementia could ease the burden on the national health insurance by incorporating these drugs. A gradual shift to a commercial health insurance reimbursement model is also expected to allow both domestic and international pharmaceutical companies to sell their drugs at higher prices, thus improving profit margins. For a long time, profit margins of pharmaceutical companies have been suppressed due to significant price cuts required by the national health insurance system.

To qualify, pharmaceutical manufacturers negotiated discounted prices with government officials, which will be offered to all commercial insurers.

In addition to Eli Lilly's Kisunla and Eisai Co.'s Leqembi for the treatment of Alzheimer’s disease, the list also includes cancer drugs from Pfizer, Johnson & Johnson, and Bristol-Myers Squibb. Many local pharmaceutical manufacturers are also on the list, including five producers of CAR-T cell therapies for cancer treatment.BeOne MedicinesIs the only company with two drugs on the list.

The government did not immediately disclose the average discount amount. Local media previously reported that the suggested price reduction range for the innovative drug list could be 15%-50%, lower than the usual 60% cut required by the National Reimbursement Drug List (NRDL).